natgillin/translations-raw huggingface dataset:
Thrombocytopenia 
Serumske transaminaze
Hepatotoxicity, predominantly in the form of asymptomatic increases in the concentrations of serum transaminases (Grade 1-4 transaminitis), has been observed during treatment with trastuzumab emtansine in clinical studies (see section 4.8). 
Med zdravljenjem s trastuzumabom emtanzinom so v kliničnih študijah opažali hepatotoksičnost, predvsem v obliki asimptomatskega zvečanja koncentracije serumskih transaminaz (transaminitis
The recommended dose of trastuzumab emtansine is 3.6 mg/kg bodyweight administered as an intravenous infusion every 3 weeks (21-day cycle). 
Priporočeni odmerek trastuzumaba emtanzina je 3,6 mg/kg telesne mase v intravenski infuziji na
Cases of haemorrhagic events, including central nervous system, respiratory and gastrointestinal haemorrhage, have been reported with trastuzumab emtansine treatment. 
Pri zdravljenju s trastuzumabom emtanzinom so poročali o primerih krvavitev, vključno s krvavitvami v osrednje živčevje, dihalih in prebavilih.
The population PK analysis showed that race did not appear to influence the PK of trastuzumab emtansine. 
Populacijska farmakokinetična analiza je pokazala, da rasa po vsem sodeč ne vpliva na farmakokinetiko trastuzumaba emtanzina.
Primary endpoints IRC-assessed progression-free survival (PFS) Number (%) of patients with event Median duration of PFS (months) Hazard ratio (stratified*) 95% CI for Hazard ratio p-value (Log-rank test, stratified*) Overall Survival (OS)** Number (%) of patients who died Median duration of survival (months) Hazard ratio (stratified*) 95% CI for Hazard ratio p-value (Log-rank test*) Key secondary endpoints Investigator-assessed PFS Number (%) of patients with event Median duration of PFS (months) Hazard ratio (95% CI) p-value (Log-rank test*) Objective response rate (ORR) Patients with measurable disease Number of patients with OR (%) Difference (95% CI) p-value (Mantel-Haenszel chi-squared test*) Duration of objective response (months) Number of patients with OR Median 95% CI OS: overall survival; PFS: progression-free survival; ORR: objective response rate; OR: objective response; IRC: independent review committee; HR: hazard ratios; CI: confidence interval * Stratified by: world region (United States, Western Europe, other), number of prior chemotherapeutic regimens for locally advanced or metastatic disease (0-1 vs. > 1), and visceral vs. non-visceral disease. 
PFS po oceni raziskovalca število (%) bolnikov z dogodkom 335 (67,5 %) mediano PFS (meseci) razmerje ogroženosti (95-% interval zaupanja) vrednost p (test log-rang*) Delež objektivnega odgovora na zdravljenje (ORR) bolniki z merljivo boleznijo število bolnikov z objektivnim odgovorom na zdravljenje (%) razlika (95-% interval zaupanja) vrednost p (Mantel-Haenszelov test hikvadrat*) Trajanje objektivnega odgovora (meseci) število bolnikov z objektivnim odgovorom mediana 95-% intervala zaupanja
(flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia) should be advised not to drive and use machines until symptoms abate. 
Bolnikom je treba naročiti, naj ne vozijo ali upravljajo strojev, če se jim pojavijo z infundiranjem povezane reakcije (zardevanje, mrzlica, pireksija, dispneja, hipotenzija, sopenje, bronhospazem in tahikardija), dokler simptomi ne minejo.
6.6 Special precautions for disposal and other handling Appropriate aseptic technique should be used. 
Uporabiti je treba ustrezen aseptični postopek in tudi ustrezne postopke za pripravo kemoterapevtikov.
Do not administer trastuzumab emtansine until platelet count recovers to £ Grade 1 (≥ 75,000/mm3), and then reduce one dose level. 
Trastuzumaba emtanzina ne uporabite, dokler se število trombocitov ne vrne na £ 1. stopnjo (≥ 75.000/mm3), nato zmanjšajte odmerek za eno stopnjo.
Hypersensitivity was reported in 2.6% of patients in MBC clinical studies with trastuzumab emtansine, with one Grade 3 and one Grade 4 events reported. 
Preobčutljivostne reakcije Preobčutljivost so opazili pri 2,6 % bolnikov z MBC v kliničnih študijah s trastuzumabom emtanzinom.
Peripheral neuropathy, mainly as Grade 1 and predominantly sensory, was reported in clinical trials of trastuzumab emtansine. 
V kliničnih preskušanjih s trastuzumabom emtanzinom so poročali o periferni nevropatiji, ki je bila v glavnem 1. stopnje in pretežno senzorična.
Do not administer trastuzumab emtansine until platelet count recovers to £ Grade 1 (≥ 75,000/mm3), and then treat at the same dose level. 
Trastuzumaba emtanzina ne uporabite, dokler se število trombocitov ne vrne na £ 1. stopnjo (≥ 75.000/mm3), nato zdravljenje nadaljujte z enakim odmerkom.
Mutagenicity 
mialgija
PHARMACEUTICAL FORM Powder for concentrate for solution for infusion. 
FARMACEVTSKA OBLIKA prašek za koncentrat za raztopino za infundiranje Bel do skoraj bel liofiliziran prašek.
· Developed disease recurrence during or within six months of completing adjuvant therapy. 
Bolniki so pred tem: · prejemali predhodno zdravljenje za lokalno napredovalo ali razsejano bolezen ali · se jim je bolezen ponovila med adjuvantnim zdravljenjem ali v šestih mesecih po koncu adjuvantnega zdravljenja.
· Periodic Safety Update Reports 
· Informacije za zdravstvene delavce
The appropriate amount of solution should be withdrawn from the vial and added to an infusion bag containing 250 mL of sodium chloride 4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9 mg/mL (0.9%) solution for infusion. 
0,45-% (4,5 mg/ml) raztopine natrijevega klorida za infundiranje ali 0,9-% (9 mg/ml) raztopine natrijevega klorida za infundiranje.
Peripheral neuropathy, mainly Grade 1 and predominantly sensory, has been reported in clinical studies with trastuzumab emtansine. 
V kliničnih študijah s trastuzumabom emtanzinom so poročali o periferni nevropatiji, ki je bila v glavnem 1. stopnje in pretežno senzorična.
Do not administer trastuzumab emtansine until platelet count recovers to £ Grade 1 (≥ 75,000/mm3), and then reduce one dose level 
Trastuzumaba emtanzina ne uporabite, dokler se število trombocitov ne vrne na £ 1. stopnjo (to je ≥ 75.000/mm3), nato zmanjšajte odmerek za eno stopnjo.
Determine the volume of the reconstituted solution required based on a dose of 3.6 mg trastuzumab emtansine/kg body weight: 
Glede na odmerek 3,6 mg trastuzumaba emtanzina na kilogram telesne mase določite potrebno količino pripravljene raztopine:
· 160 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 8 mL of sterile water for injection into the vial. 
· 160-mg viala trastuzumaba emtanzina: S sterilno injekcijsko brizgo počasi injicirajte v vialo
Blood and lymphatic system disorders 
Žilne bolezni krvavitev hipertenzija
Talk to your doctor or nurse before you are given Kadcyla if: · you have ever had a serious infusion-related reaction from using trastuzumab characterised by symptoms such as flushing, chills, fever, shortness of breath, difficulty breathing, rapid heartbeat or a drop in blood pressure. 
za katero so značilni simptomi, kot so rdečica, mrazenje, povišana telesna temperatura, kratka sapa, težave pri dihanju, hiter srčni utrip ali padec krvnega tlaka,
Other side effects include 
Drugi neželeni učinki Zelo pogosti:
Do not administer trastuzumab emtansine. 
Prenehajte uporabljati trastuzumab emtanzin.
NAME OF THE MEDICINAL PRODUCT Kadcyla 160 mg powder for concentrate for solution for infusion trastuzumab emtansine 
Kadcyla 160 mg prašek za koncentrat za raztopino za infundiranje trastuzumab emtanzin
Cardiac disorders 
Simptomatsko kongestivno srčno popuščanje
You should tell your doctor immediately if you notice any of the above symptoms. 
Če opazite katerega od navedenih neželenih učinkov, morate to nemudoma povedati zdravniku.
NAME OF THE MEDICINAL PRODUCT Kadcyla 100 mg powder for concentrate for solution for infusion trastuzumab emtansine 
Kadcyla 100 mg prašek za koncentrat za raztopino za infundiranje trastuzumab emtanzin
The use of 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required for the infusion when the concentrate for infusion is diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. 
Če je koncentrat za infundiranje razredčen z 0,9-% (9 mg/ml) raztopino natrijevega klorida za infundiranje, je treba za infundiranje uporabiti 0,20- ali 0,22-mikronski polietersulfonski (PES) filter v liniji.
STATEMENT OF ACTIVE SUBSTANCE(S) One vial of powder for concentrate for solution for infusion contains 100 mg of trastuzumab emtansine. 
Ena viala praška za koncentrat za raztopino za infundiranje vsebuje 100 mg trastuzumaba emtanzina.
Instructions for reconstitution · 100 mg trastuzumab emtansine vial: Using a sterile syringe, slowly inject 5 mL of sterile water for injection into the vial. 
· 100-mg viala trastuzumaba emtanzina: S sterilno injekcijsko brizgo počasi injicirajte v vialo
Posology 
Izrazitost
Do not substitute or combine trastuzumab emtansine with or for trastuzumab 4. 
Ne zamenjujte trastuzumaba emtanzina s trastuzumabom, obeh zdravil ne uporabljajte sočasno.
Do not use if reconstituted solution is cloudy or discoloured. 
Če je pripravljena raztopina motna ali spremenjene barve, je ne uporabite.
Cases of interstitial lung disease (ILD), including pneumonitis, some leading to acute respiratory distress syndrome or a fatal outcome, have been reported in clinical studies with trastuzumab emtansine (see section 4.8). 
Pri nekaterih je prišlo do sindroma akutne respiratorne stiske ali smrti (glejte poglavje 4.8).
Trastuzumab emtansine has not been studied in patients with severe hepatic impairment. 
Pri bolnikih, zdravljenih s trastuzumabom emtanzinom, so opažali resne hepatobiliarne zaplete,
peripheral neuropathy until resolution to ≤ Grade 2. 
4. stopnje, in sicer za toliko časa, da se zmanjša na ≤ 2. stopnjo.
Radiotherapy-Related Pneumonitis 
vključno s pnevmonitisom.
3 August 2009 Doc. 
3 avgust 2009 Doc.
The final opinion was converted into a Decision by the European Commission on 3 August 2009. 
Končno mnenje je bilo spremenjeno v Odločbo Evropske komisije dne 3 avgusta 2009.
The Mutual Recognition Procedure started on 28 February 2008. 
Postopek medsebojnega priznavanja se je začel 28. februarja 2008.
The application was submitted in the framework of Article 32 of Directive 2001/82/EC, as amended, where the Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, France, Germany, Ireland, Italy, The Netherlands, Poland, Portugal and Spain. 
Vloga je bila predložena v skladu s členom 32 Direktive 2001/82/ES, kakor je bila spremenjena, pri čemer je bilo Združeno kraljestvo referenčna država članica, Avstrija, Belgija, Francija, Nemčija, Irska, Italija, Nizozemska, Poljska, Portugalska in Španija pa zadevne države članice.
Florfenicol is a synthetic broad spectrum antibiotic with a range of activity, including many Gramnegative and Gram-positive organisms. 
Florfenikol je sintetični antibiotik s širokim spektrom delovanja, tudi proti gramnegativnim in grampozitivnim organizmom.
Ref.EMEA/313849/2009 
EMEA/520063/2009
Due to concerns raised by Germany and The Netherlands during the Mutual Recognition Procedure that Fenflor 300 mg/ml solution for injection for cattle could present a potential serious risk to the environment, the United Kingdom referred the matter to the EMEA on 31 July 2008 under Article 33(4) of Directive 2001/82/EC. 
Zaradi zadržkov, ki sta jih med postopkom medsebojnega priznavanja izrazili Nemčija in Nizozemska, da bi lahko Fenflor 300 mg/ml raztopina za injiciranje za govedo pomenila morebitno resno okoljsko tveganje, je Združeno kraljestvo dne 31. Julija 2008 vprašanje napotilo na agencijo EMEA v skladu s členom 33(4)Direktive 2001/82/ES.
OPINION FOLLOWING AN ARTICLE 33 (4)1 REFERRAL FOR FENFLOR 300 MG/ML SOLUTION FOR INJECTION FOR CATTLE International Non-Proprietary Name (INN): Florfenicol 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 33(4)1 ZA FENFLOR 300 MG/ML RAZTOPINA ZA INJICIRANJE ZA GOVEDO MEDNARODNO NELASTNIŠKO IME (INN):
The Marketing Authorisation Holder, Gosmore Ltd, submitted an application via mutual recognition for Fenflor 300 mg/ml solution for injection for cattle, on the basis of the marketing authorisation granted by the United Kingdom. 
Imetnik dovoljenja za promet z zdravilom, družba Gosmore Ltd., je vložil prošnjo za postopek medsebojnega priznavanja za zdravilo Fenflor 300 mg/ml, raztopino za injiciranje za govedo na podlagi dovoljenja za promet, ki ga je bilo odobreno v Združenem kraljestvu.
Moreover, the intended uses do not require medical supervision. 
Poleg tega predvidena uporaba ne zahteva zdravniškega nadzora.
Agrimony should only be used in adults and children over the age of 12 years. 
Zel navadnega repika se lahko uporablja samo pri odraslih in otrocih, starejših od 12 let.
This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU). 
To pomeni, da je kljub pomanjkljivim dokazom iz kliničnih preskušanj učinkovitost teh zdravil rastlinskega izvora verjetna in da obstajajo dokazi, da so se na navedene načine varno uporabljala že vsaj 30 let (najmanj 15 let tudi v EU).
These may also be used to prepare liquid extracts with water and alcohol. 
Ti se lahko uporabljajo tudi za pripravo tekočih izvlečkov z vodo in alkoholom.
It can also be applied to the skin for relief of minor inflammation and small superficial wounds. 
Prav tako se lahko nanaša na kožo za lajšanje blagega vnetja in majhnih površinskih ran.
Agrimony preparations are obtained by comminuting (reducing into tiny pieces) the dried plant parts. 
Pripravki zeli navadnega repika se pridobivajo z drobljenjem (zmanjševanjem na majhne delce) posušenih rastlinskih delov.
The HMPC conclusions on the use of agrimony medicines for the relief of mild diarrhoea, mild inflammation of the mouth and throat, skin inflammation and wounds are based on their ‘traditional use' in these conditions. 
Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo zel navadnega repika, za lajšanje blage driske, blagega vnetja ust ter žrela, kožnega vnetja in ran temeljijo na njihovi „tradicionalni uporabi“ pri teh stanjih.
This summary is not intended to provide practical advice on how to use medicines containing agrimony. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel navadnega repika.
For further information, see the HMPC assessment report. 
Za podrobnejše informacije glejte poročilo odbora HMPC o oceni zdravila.
Agrimony is the common name for the flowering tops of the plant Agrimonia eupatoria L. The plant is cultivated or gathered to obtain the plant parts for medicinal use. 
Zel navadnega repika je splošno ime za cvetoče vršičke rastline Agrimonia eupatoria L. Rastlina se goji ali nabira za pridobivanje rastlinskih delov za medicinsko uporabo.
Agrimony can also be found in combination with other herbal substances in some herbal medicines. 
Zel navadnega repika je lahko na voljo tudi v kombinaciji z drugimi rastlinskimi snovmi v nekaterih zdravilih rastlinskega izvora.
The HMPC noted the lack of clinical studies with agrimony, but took into account the well documented use of this herbal medicine for the above uses. 
Odbor HMPC je izpostavil pomanjkanje kliničnih študij z zeljo navadnega repika, vendar je upošteval dobro dokumentirano uporabo tega zdravila rastlinskega izvora pri zgoraj navedenih področjih uporabe.
They are also available as liquids to be applied to the skin or used as a bath additive. 
Prav tako so na razpolago kot tekočine za nanos na kožo ali dodatki za kopel.
Agrimony EMA/HMPC/332849/2015 
Zel navadnega repika EMA/HMPC/332849/2015
Further information on the risks associated with agrimony medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo zel navadnega repika, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of agrimony. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo zeli navadnega repika.
Information on the use and licensing of agrimony medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in dovoljenjih za promet z zdravili, ki vsebujejo zel navadnega repika, v državah članicah EU se obrnite na pristojni nacionalni organ.
The HMPC concluded that, on the basis of its long-standing use, agrimony can be taken by mouth for the relief of mild diarrhoea, or used as a gargle to relieve mild inflammation of the mouth and throat. 
Odbor HMPC je zaključil, da se lahko zel navadnega repika na podlagi svoje dolgotrajne uporabe uživa peroralno (skozi usta) za lajšanje blage driske ali uporablja kot raztopina za grgranje za lajšanje blagega vnetja ust ter žrela.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing agrimony. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo zel navadnega repika.
Any applications for the licensing of medicines containing agrimony have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo zel navadnega repika, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
treatment, or if mouth, throat or skin symptoms persist for more than a week during treatment. 
Če driska med zdravljenjem traja več kot tri dni ali če simptomi ust, žrela in kože trajajo več kot teden dni, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
Further information on the HMPC assessment of agrimony medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo zel navadnega repika, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
How are agrimony medicines approved in the EU? 
Kako so zdravila, ki vsebujejo zel navadnega repika, odobrena v EU?
Herbal medicines containing agrimony are usually available as herbal teas to be drunk, or as gargles. 
Zdravila rastlinskega izvora, ki vsebujejo zel navadnega repika, so navadno na voljo v obliki rastlinskih čajev za pitje ali raztopin za grgranje.
What evidence supports the use of agrimony medicines? 
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo zel navadnega repika?
Detailed instruction on how to take agrimony medicines and who can use them can be found in the package leaflet that comes with the medicine. 
Podrobna navodila o jemanju zdravil, ki vsebujejo zel navadnega repika, in o tem, kdo lahko ta zdravila jemlje, so v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
For more information about treatment with Agrimony medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravili, ki vsebujejo zel navadnega repika, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using agrimony medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. 
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
What are the risks associated with agrimony medicines? 
Kakšna tveganja so povezana z zdravili, ki vsebujejo zel navadnega repika?
What is agrimony? 
Kaj je zel navadnega repika?
Other information about agrimony medicines 
Druge informacije o zdravilih, ki vsebujejo zel navadnega repika
The European Commission granted a marketing authorisation valid throughout the European Union for Toviaz on 20 April 2007. 
Evropska komisija je dovoljenje za promet z zdravilom Toviaz, veljavno po vsej Evropski uniji, odobrila dne 20. aprila 2007.
Toviaz fesoterodine 
Toviaz fesoterodin
Toviaz must also not be used in patients with: 
Zdravila Toviaz ne smejo uporabljati bolniki z:
Based upon individual response, the dose may be increased to 8 mg once daily. 
Glede na odziv posameznega bolnika na zdravilo, se lahko odmerek poveča na 8 mg enkrat na dan.
The full EPAR for Toviaz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Toviaz je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It blocks some receptors in the body, the muscarinic receptors. 
Zavira nekatere receptorje v telesu, imenovane muskarinski receptorji.
Other information about Toviaz 
Druge informacije o zdravilu Toviaz
This is a summary of the European public assessment report (EPAR) for Toviaz. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Toviaz.
The patient normally gets the full effect of the treatment after two to eight weeks. 
Poln učinek zdravljenja se pri bolniku navadno pokaže po 2 do 8 tednih.
This number was reduced by 1.74 and 1.86 with the 4 mg dose of Toviaz and by 1.94 with the 8 mg dose. 
To število se je zmanjšalo za 1,74 in 1,86 z 4-miligramskim odmerkom zdravila Toviaz in za 1,94 z 8-miligramskim odmerkom.
Prolonged-release means that fesoterodine is released slowly from the tablet over a few hours. 
Podaljšano sproščanje pomeni, da se fesoterodin iz tablete sprošča počasi v trajanju nekaj ur.
This helps Toviaz to prevent unwanted urination. 
Na ta način zdravilo Toviaz pomaga preprečiti neželeno uhajanje urina.
Before treatment, patients needed to urinate about 12 times in 24 hours. 
Pred zdravljenjem je bolnik uriniral okoli 12-krat v 24 urah.
What benefit has Toviaz shown during the studies? 
Kakšne koristi je zdravilo Toviaz izkazalo med študijami?
The most common side effect with Toviaz (seen in more than 1 patient in 10) is dry mouth. 
Najpogostejši neželeni učinek zdravila Toviaz (opažen pri več kot 1 bolniku od 10) so suha usta.
These include medicines such as ketoconazole and itraconazole (used to treat fungal infections), atazanavir, indinavir, nelfinavir, ritonavir and saquinavir (medicines used in HIV-positive patients), clarithromycin and telithromycin (antibiotics), and nefazodone (used to treat depression). 
Mednje spadajo zdravila, kot so ketokonazol in itrakonazol (za zdravljenje glivičnih okužb), atazanavir, indinavir, nelfinavir, ritonavir in sakvinavir (zdravila za bolnike, okužene z virusom HIV), klaritromicin in telitromicin (antibiotika) ter nefazodon (za zdravljenje depresije).
The CHMP decided that Toviaz's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Toviaz večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.